Advanced Oncotherapy has appointed Professor Steve Myers OBE and Hans von Celsing as Non-Executive Directors. Hans von Celsing will become Senior Independent Non-Executive Director.
The company announced its intention to appoint Professor Myers on November 1, 2016. Professor Myers has been part of the Advanced Oncotherapy Leadership Team since his appointment as Executive Chairman of the company’s subsidiary ADAM S.A., in November 2015.
Hans von Celsing, commenting on his new appointment said the he was impressed with the quality of the team, the deep technical knowledge they have and the company’s collaboration with CERN, the preeminent particle physics institute.
Prior to this appointment, Hans von Celsing was an Adviser to Mevion Medical Systems for eight years and supported their international expansion in Europe and Asia.
Michael Sinclair, Executive Chairman of Advanced Oncotherapy said: “Steve and Hans are hugely experienced in their respective fields. Steve’s background at CERN and his work with accelerator technology and the medical application of this technology have been invaluable to the business since he joined us in 2015. Hans has a wealth of knowledge in the sector and his CV speaks for itself in terms of his experience at Board level.”
Tim Lebus, Non-Executive Director, will stand down.
Commenting on Lebus stand down, Sinclair said: “Finally, I would like to thank Tim Lebus for his immense contribution to the Board over the last three and a half years. Tim’s experience in private equity and banking has been incredibly helpful as the company has progressed and we are very grateful for his guidance and we wish him well for the future.”